Trial Profile

A Phase I Study of DNL758 in Healthy volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eclitasertib (Primary)
Indications Psoriasis; Rheumatoid arthritis
Focus Adverse reactions
Sponsors Sanofi

Most Recent Events

07 Aug 2020 Results presented in the Denali Therapeutics Inc media release.
07 Aug 2020 Status changed from recruiting to completed, according to a Denali Therapeutics Inc media release.
05 Aug 2019 According to a Denali Therapeutics media release, Sanofi has commenced dosing of DNL758 in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com